- The move into impact of the private equity giants suggests at least demand from pension funds, endowments and sovereign wealth funds that need to write large checks.
An innovative financing mechanism for drugs for neglected diseases is providing a return for impact investors. Novo Nordisk, the Danish pharmaceutical giant, disclosed that it is the buyer of a “priority review voucher” from Medicines Development for Global Health, an Australian nonprofit that won U.S. Food and Drug Administration approval for moxidectin as a treatment
- A contrarian story is emerging in cleantech venture capital.
- As the world’s largest asset manager, with a $6.5 trillion portfolio, BlackRock “has the power to lead globally to address climate risk, yet to-date it remains a laggard,” says Tim Buckley of IEEFA.
- News of the latest cohort comes as Techstars secured $42 million in equity financing to expand its global footprint.
- The Delta Fund committed half of the fund’s capital. 3rd Creek Foundation, Chintu Gudiya Foundation, Galloway Family Foundation, Vibrant Village Foundation and the Norwegian Interhands Foundation provided the rest.
- LIC VC and Jeremy Oppenheim, founder of sustainable investment fund SYSTEMIQ, also participated.